Indian Gleevec Direct Mail Network 13621079267 The efficacy of Indian Gleevec

,) / ' h', After Gleevec resistance, general clinicians will recommend patients to use dasatinib for treatment. Dasatinib is expensive, so many patients inquire about whether there are other alternatives. drug. Drug Post reviewed relevant information and found an article about Gleevec,) / ' h', a clinical treatment case of taking Nexavar after drug resistance, which is now excerpted for your reference.
dd ,) dd dh / ' h', dd , Nexavar is effective in the treatment of Gleevec-resistant gastrointestinal stromal tumors
dd ,) dd dh / ' h', dd In the report: Research in A multicenter phase II study of Nexavar was conducted in patients with stromal tumors whose disease was confirmed to be progressive and expressed according to the Solid Tumor Response Evaluation Criteria during treatment. Nexavar was effective in patients with Gleevec-resistant gastrointestinal stromal tumors. The effect is clear and the disease control rate is %.
dd ,) dd dh / ' h', dd , Studies also show that
even for patients with drug-resistant primary stromal tumors, it may still prolong the disease control period.
dd ,) dd dh / ' h', dd , Special note: Although it is well tolerated by patients with stromal tumors, it often needs to be used at a reduced dosage.
dd ,) dd dh / ' h', dd ,
, Study clinical trial data
dd ,) dd dh / ' h', dd , 1.
, Trial time
dd ,) dd dh / ' h', dd year month to year month
dd ,) dd dh / ' h', dd , two
, , clinical trial objectives
dd ,) dd dh / ' h', dd The goal of the clinical trial is to study the objective effectiveness of Nexavar treatment. The study adopts Simon's min-max (mm) two-stage design. For the first stage, 10% of patients need to be effective. For further research, 10% of patients with M/resistant resistance are required to be effective.
dd ,) dd dh / ' h', dd , 3
, , usage and dosage
dd ,) dd dh / ' h', dd Dosage: The patient takes Nexavar orally, daily Second-rate.
dd ,) dd dh / ' h', dd , four
, , test subjects
dd ,) dd dh / ' h', dd The researchers included patients ( Example M drug-resistant, case M / drug-resistant). Patient characteristics are
dd ,) dd dh / ' h', dd % are male, median age is years (~years)
dd ,) dd dh / ' h', dd Physical status is %/ %/
dd ,) dd dh / ' h', dd Liver metastasis
dd ,) dd dh / ' h', dd Primary drug resistance (months of disease progression): %,
dd ,) dd dh / ' h', dd Baseline mutations are exon %, exon %, platelet derived growth factor receptor h (h) %.
dd ,) dd dh / ' h', dd , five
, , medication cycle
dd ,) dd dh / ' h', dd The median medication cycle is cycle (~). % Use R months, % years. % of patients with primary resistance were treated with R for R or D months.
dd ,) dd dh / ' h', dd , Note
% of patients reduce medication.
dd ,) dd dh / ' h', dd , six
, , trial results
dd ,) dd dh / ' h', dd The median progression-free survival time is .months (% is .~.).
dd ,) dd dh / ' h', dd The median overall survival is . months (% is .~.).
dd ,) dd dh / ' h', dd The annual survival rate is %,
dd ,) dd dh / ' h', dd The annual survival rate is %.
dd ,) dd dh / ' h', dd % of patients (case M resistant, case M/resistant) had partial response (R),
dd ,) dd dh / ' h', dd % (cases M drug-resistant, case M/drug-resistant) are in stable condition (D).
dd ,) dd dh / ' h', dd The disease control rate (R+D) is %.
dd ,) dd dh / ' h', dd , seven
, , toxic reactions
dd ,) dd dh / ' h', dd Grade /toxicity (% of patients) for hands and feet Syndrome%, hypertension%, diarrhea%, hypophosphatemia%, gastrointestinal bleeding%, thrombosis%, gastrointestinal perforation%, intracranial hemorrhage%.